Pulmonary Complications in Patients with Hematological Disorders: Pathobiological Bases and Practical Approach

ABSTRACT

Pulmonary complications occur in up to 40 to 60% of patients with hematological disorders during the disease course and considerably influence morbidity and mortality. The main factors making the lung a clinically significant targeted organ in these patients may be summarized as follows.

In the lung parenchyma a variety of inflammatory cells whose precursors are in the bone marrow pass through, park in, proliferate, and release microbicidal and cytohistotoxic substances.

Constitutive parenchymal lung cells (bronchiolar and alveolar epithelial cells, endothelial cells, “interstitial” cells) may be a distinctive target for toxic substances or may have an important part in the inflammatory/reactive and reparative processes after an injury event.

Pathogenic agents are allowed to reach the lung very easily through either or both the airways and the vascular bed and accumulate there in large amounts.

Inflammatory/immunologic reactions may be particularly weak or, on the contrary strong, in the lungs either spontaneously or due to toxic action of drugs and radiation or to the immunodeficiency induced by hematological disorders, and finally to the presence of immunomodulatory viruses.

The distinctive anatomical structure and function of the lung parenchyma (interactions between air spaces and capillary bed-gas exchange units) may render localized parenchymal damage clinically relevant.

Allogeneic reactions may be overexpressed in the lung or the kinetics of the developing of graft versus host disease (GVHD)-related lung injury may be markedly different from the kinetics of GVHD in other organs.

Hematological disorders may harbor in lung parenchymal structures at the onset (i.e., lympho-/myeloproliferative disorders primary in the lung) or during the disease course.

Genetic predisposition, although probably involved, is not yet well understood.

This article reviews the pathobiological bases of lung injury occurring in subjects with hematological disorders and suggests a practical diagnostic approach to these pulmonary complications.

KEYWORDS

Chemokines - pentraxins - immunocompromised host - high resolution CT scan - bronchoscopic procedures

REFERENCES

• 1 Jabot-Lestang L, Maitre B, Cordonnier C. Puomon et maladies hematologique. Encyclopedie Medico-Chir. 2003: 1-12
• 2 Poletti V, Trisolini R, Tura S. Pulmonary disease in patients with hematologic malignancies.  Sarcoidosis Vasc Diffuse Lung Dis. 2002;  19 29-45
• 3 Poletti V, Salvucci M, Zanchini R et al.. The lung as a target organ in patients with hematologic disorders.  Haematologica. 2000;  85 855-864
• 4 Worthen G S, Nick J A. Leukocyte accumulation in the lung. In: Fishman's Pulmonary Diseases and Disorders. New York; McGraw-Hill 1998: 325-346
• 5 Drost E M, Kassabian G, Meiselman H J, Gelmont D, Fisher T C. Increased rigidity and priming of polymorphonuclear leukocytes in sepsis.  Am J Respir Crit Care Med. 1999;  159 1696-1702
• 6 Abramson S L, Malech H L, Gallin J I. Neutrophils. In: Crystal RG, West JB The Lung:Scientific Foundation. New York; Raven 1991: 553-563
• 7 Hogg J C. Neutrophil traffic. In: Crystal RG, West JB The Lung: Scientific Foundation. New York; Raven 1991: 565-577
• 8 Thomas Jr C F, Limper A H. Pneumocystis pneumonia.  N Engl J Med. 2004;  350 2487-2498
• 9 Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug induced lung disease.  Clin Chest Med. 2004;  25 25-35
• 10 Linssen K C, Jacobs J A, Poletti V, van Mook W, Drent M. Reactive type II pneumocytes in bronchoalveolar lavage fluid.  Acta Cytol. 2004;  48 497-504
• 11 Cordonnier C, Fleury-Feith J, Escudier E, Atassi K, Bernaudin J F. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients.  Am J Respir Crit Care Med. 1994;  149 788-794
• 12 Kaminsky D A, Hurwitz C G, Olmstead J I. Pulmonary leukostasis mimicking pulmonary embolism.  Leuk Res. 2000;  24 175-178
• 13 Toews G B. Host defences. In: Albert RK, Spiro S, Jett JR Clinical Respiratory Medicine. Philadelphia; Mosby 2004: 129-141
• 14 Delclaux, Azoulay E. Inflammatory response to infectious pulmonary injury.  Eur Respir J. 2003;  42(s) 10s-14s
• 15 Aderem A, Ulevitch R J. Toll-like receptors in the induction of the innate immune response.  Nature. 2000;  406 782-787
• 16 Ding K, Shibui A, Wang Y, Takamoto M, Matsuguchi T, Sugane K. Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia.  Microbes Infect. 2005;  7 195-203
• 17 Garlanda C, Hirsch E, Bozza S et al.. Nonredundant role of the long pentraxin PTX3 in anti-fungal innate immune response.  Nature. 2002;  420 182-186
• 18 Riches D WH, Scott Worthen G, Augustin A, Lapadat R, Chan E D. Inflammation in the pathogenesis of interstitial lung diseases. In: Schwarz MI, King TE Jr Interstitial Lung Disease. Hamilton, BC; Decker 2003: 187-220
• 19 Agostini C, Chilosi M, Zambello R, Trentin L, Semenzato G. Pulmonary immune cells in health and disease: lymphocytes.  Eur Respir J. 1993;  6 1378-1401
• 20 Zhang Y, Joe G, Hexner E, Zhu J, Emerson S G. Alloreactive memory T cells are responsible for the persistence of graft-versus-host-disease.  J Immunol. 2005;  174 3051-3058
• 21 Vakkila J, Thomson A W, Hovi L, Vettenranta K, Saarinen-Pihkala U M. Circulating dendritic cell subset levels after allogeneic stem cell transplantation in children correlate with time post transplant and severity of acute graft versus host disease.  Bone Marrow Transplant. 2005;  35 501-507
• 22 McCormack F X, Shannon J M. Role of the alveolar epithelium in the pathogenesis of pulmonary fibrosis. In: Schwarz MI, King TE Jr Interstitial Lung Disease. Hamilton, BC; Decker 2003: 221-244
• 23 Tanoue L T. Pulmonary toxicity associated with chemotherapeutic agents. In: Fishman AP Fishman's Pulmonary Diseases and Disorders. New York; McGraw-Hill 1998: 480-489
• 24 Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation.  Respiration. 2004;  71 301-326
• 25 Fishman J A, Rubin R H. Infection in organ-transplant recipients.  N Engl J Med. 1998;  338 1741-1751
• 26 Hunninghake G W, Monick M M, Geist L J. Cytomegalovirus infection: regulation of inflammation.  Am J Respir Cell Mol Biol. 1999;  21 150-152
• 27 Mocarski Jr E S, Courcelle C T. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM Fields Virology. Philadelphia; Lippincott Williams & Wilkins 2001: 2673
• 28 Piovan E, Tosello V, Indraccolo S et al.. Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation.  Blood. 2005;  105 931-939
• 29 Tobin M. Advances in mechanical ventilation.  N Engl J Med. 2001;  344 1986-1996
• 30 Eutamene H, Theodorou V, Schmidlin F et al.. LPS-induced lung inflammation is linked to increased epithelial permeability: role of MLCK.  Eur Respir J. 2005;  25 789-796
• 31 Hornsey S, Cullen B M, Myers R, Walker H C, Hedges M J. Radiation injury in mouse lung: dependence on oxygen levels in the inspired gas.  Int J Radiat Biol Relat Stud Phys Chem Med. 1986;  50 471-479
• 32 Gulbahce H E, Pambuccian S E, Jessurun J et al.. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis.  Am J Clin Pathol. 2004;  121 205-210
• 33 Ewer M S, Martin F J, Henderson C et al.. Cardiac safety of liposomal anthracyclines.  Semin Oncol. 2004;  31(Suppl 13) 161-181
• 34 Wiedermann H P. Toward an understanding of idiopathic pneumonia syndrome after bone marrow transplantation.  Crit Care Med. 1999;  27 2040-2041
• 35 Panoskaltsis-Mortari A, Taylor P A, Yaegar T M et al.. The critical early proinflammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogenic recipients are due to donor T cell infusion and potentiated by cyclophosphamide.  J Clin Invest. 1997;  100 1015-1027
• 36 Qureshi M A, Girgis R E, Dandapantula H K, Abrams J, Soubani A O. Increased exhaled nitric oxide following autologous peripheral hematopoietic stem-cell transplantation.  Chest. 2004;  125 281-287
• 37 Hildebrandt G C, Duffner U A, Olkiewicz K M et al.. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation.  Blood. 2004;  103 2417-2426
• 38 Patriarca F, Skert C, Sperotto A et al.. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation.  Bone Marrow Transplant. 2004;  33 751-758
• 39 Nicholson A G, Poletti V, Semenzato G. Lymphoprolipherative disease. In: Gibson J, Geddes D, Costabel U, Sterk P, Corrin B Respiratory Medicine. 3rd ed. London; Harcourt Health Sciences 2003: 1694-1707
• 40 Coy D L, Ormazabal A, Godwin J D, Lalani T. Imaging evaluation of pulmonary and abdominal complications following hematopoietic stem cell transplantation.  Radiographics. 2005;  25 305-317
• 41 Heussel C P, Kauczor H U, Heussel G U et al.. Pneumonia in febrile neutropenic patients and bone marrow and blood stem cell transplant recipients: use of high resolution computed tomography.  J Clin Oncol. 1999;  17 928-933
• 42 Poletti V, Chilosi M, Olivieri D. Diagnostic invasive procedures in diffuse infiltrative lung diseases.  Respiration. 2004;  71 107-119
• 43 Rano A, Agusti C, Jmenez P et al.. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using noninvasive and bronchoscopic procedures.  Thorax. 2001;  56 379-387
• 44 Costabel U, Guzman J. Bronchoalveolar lavage in interstitial lung disease.  Curr Opin Pulm Med. 2001;  7 255-261
• 45 Rano A, Agusti C, Jmenez P et al.. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using noninvasive and bronchoscopic procedures.  Thorax. 2001;  56 379-387
• 46 Wong P W, Stefance T, Brown K, White D A. Role of fine-needle aspirates of focal lesions in patients with hematologic malignancies.  Chest. 2002;  121 527-532
• 47 White D A, Wong P W, Downey R. The utility of open lung biopsy in hematologic patients with pulmonary infiltrates.  Am J Respir Crit Care Med. 2000;  161 723-729
• 48 Zihlif M, Khanchandani G, Ahmed H P, Soubani A O. Surgical lung biopsy in patients with haematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis.  Am J Hematol. 2005;  78 94-99